Tag: M.W=350-400

Patel, Priyadarshini Chirag published the artcileFormulation and evaluation of sublingual tablets containing esomeprazole sodium, Application of Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, the publication is World Journal of Pharmacy and Pharmaceutical Sciences (2018), 7(6), 954-965, database is CAplus.

The objective of the present research work was to develop and optimize a sublingual tablet of Esomeprazole sodium which is indicated for the treatment of gastro oesophageal reflux disease, by direct compression method. The tablets were prepared using four different superdisintegrants such as sodium starch glycolate, cross carmellose sodium, crosspovidone and Indion 414. The prepared tablets were evaluated for their phys. characteristics and in vitro drug release properties. In vitro release study was carried out using USP dissolution apparatus 2. The results revealed that the batch of tablets (F-13) formulated containing Indion 414 provides short wetting time of 8.2 s and in vitro disintegration time of 18.7 s, which facilitates its faster disintegration and drug content of 99.54%, and in-vitro drug release was found to be in formulation F-13 i.e. 99.86% within 120 s. From the above results, it indicate that Formulation F-13 emerged as the overall best formulation based on drug release characteristics with pH 6.8 phosphate buffer as dissolution medium. Stability studies were carried out which indicated that the selected formulation F-13 was found to be stable.

World Journal of Pharmacy and Pharmaceutical Sciences published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C17H18N3NaO3S, Application of Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Singh, Brahma N. published the artcileCompatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration, Computed Properties of 161796-78-7, the publication is American Journal of Health-System Pharmacy (2011), 68(22), 2163-2169, database is CAplus and MEDLINE.

Purpose: The phys. compatibility of ceftaroline fosamil with commonly used medications and diluents (a total of 73 drugs in 219 admixtures) during simulated Y-site administration was evaluated. Methods. Duplicate 5-mL samples of ceftaroline fosamil (2.22 mg/mL) in 5% dextrose injection, 0.9% sodium chloride injection, and lactated Ringer’s injection were combined at a 1:1 ratio with samples of 73 drugs (diluted or undiluted). Visual examinations were performed with the unaided eye in fluorescent light and with the aid of a Tyndall beam; the turbidity and particulate content of each sample were also measured. The compatibility of ceftaroline fosamil with propofol was evaluated by visually inspecting for emulsion separation and particle formation after centrifugation. All evaluations were performed within 15 min of sample preparation and at one and four hours after preparation Results: Ceftaroline fosamil was phys. compatible with 64 drugs in a combination of 196 admixtures for at least four hours, exhibiting color, clarity, turbidity, and microparticle content similar to those of control solutions Signs of phys. incompatibility, including visible precipitation, increased turbidity, and microparticle formation, were observed with 9 drugs in 23 admixtures during the four-hour observation period. Conclusion: Of the 73 drugs evaluated, 64 were compatible and 7 were incompatible with ceftaroline fosamil 2.22 mg/mL in 3 standard infusion solutions Nine drugs in 23 admixtures were observed to exhibit signs of incompatibility with ceftaroline fosamil within four hours of mixing; those drugs should not be simultaneously administered via a Y-site with ceftaroline preparations

American Journal of Health-System Pharmacy published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C11H22N2O4, Computed Properties of 161796-78-7.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Yang, Lin published the artcileDetermination of esomeprazole sodium for injection by HPLC, Formula: C17H18N3NaO3S, the publication is Huaxue Gongchengshi (2016), 30(1), 31-32, 4, database is CAplus.

Objective: To establish a method for the determination of esomeprazole sodium for injection by HPLC. Method: The anal. was performed on a Diamonsil C18 column (4.6 mm×150 mm, 5 μm) with the mobile phase of 20 mM potassium dihydrogen phosphate buffer solution (pH6.86)-methanol (35:65, V/V) at a flow rate of 1 mL·min^-1. The wavelength used for detection was 302 nm. Result: The calibration curve of esomeprazole was linear in the range of 50âˆ?00 μg·mL^-1 (r=-0.9997). The mean recoveries were 99.2% (RSD=0.6%, n=9). Conclusion: The method was proved to be rapid, simple and accurate and have been successfully applied for determination of esomeprazole sodium for injection.

Huaxue Gongchengshi published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C11H21BF4N2O2, Formula: C17H18N3NaO3S.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Murray-Smith, Richard J. published the artcileManaging emissions of active pharmaceutical ingredients from manufacturing facilities: An environmental quality standard approach, Recommanded Product: Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, the publication is Integrated Environmental Assessment and Management (2012), 8(2), 320-330, database is CAplus and MEDLINE.

Active pharmaceutical ingredient (API) residues have been found to be widespread in the aquatic environment, albeit in most cases at trace levels, with the route to the environment predominantly being via therapeutic use and subsequent excretion to sewer. Although manufacturing discharges may be a low overall contributor to environmental concentrations, they need to be managed effectively so that they do not adversely affect the local receiving environment. In order to achieve this, a risk-based approach is proposed that identifies the long-term and short-term concentrations, referred to as environmental reference concentrations (ERCs) and maximum tolerable concentrations (MTCs), resp., of an API which should not be exceeded in the aquatic environment receiving effluent from pharmaceutical manufacturing sites. The ERC approach is based on established environmental quality standard concepts currently used in much national and international legislation. Building on these concepts, the approach takes into account indirect exposure of potential consumers such as fish-eating mammals and humans, as well as primary producers (e.g., algae) and primary and secondary consumers (e.g., invertebrates and fish). Although chronic toxicity data are preferred for ERC derivation, acute data, with appropriate considerations of uncertainty, may be used when chronic data are not available. This approach takes all available information into account, particularly for older established medicines that may predate current regulatory requirements for environmental data, and consequently helps prioritize resources for environmental testing. The ERC approach has been applied to 30 of AstraZeneca’s APIs. Merits of the approach are discussed together with opportunities for potential future refinement. Integr Environ Assess Manag 2012; 8: 320-330. © 2011 SETAC.

Integrated Environmental Assessment and Management published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C17H18N3NaO3S, Recommanded Product: Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Song, Weiguo published the artcileSynthesis of esomeprazole magnesium, Computed Properties of 161796-78-7, the publication is Zhongguo Yiyao Gongye Zazhi (2013), 44(8), 744-746, database is CAplus.

Esomeprazole magnesium, a proton pump inhibitor, was synthesized from 2-hydroxymethyl-3,5-dimethyl-4-nitropyridine by chlorination, condensation, asym. oxidation, methoxylation and then reacted with magnesium chloride. The overall yield was 73.6% (based on 2-hydroxymethyl-3,5-dimethyl-4-nitropyridine).

Zhongguo Yiyao Gongye Zazhi published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C10H20N2O6S2, Computed Properties of 161796-78-7.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Mei, Xiao-Meng published the artcileEnantioseparation characteristics of the chiral stationary phases based on natural and regenerated chitins, HPLC of Formula: 161796-78-7, the publication is Journal of Separation Science (2017), 40(8), 1710-1717, database is CAplus and MEDLINE.

Natural and regenerated chitins were derivatized with 3,5-dimethyphenyl isocyanate. The corresponding chiral stationary phases were prepared by coating the resulting chitin derivatives on 3-aminopropyl silica gel. The swelling capacity of the chitin derivatives, enantioseparation capability, as well as eluents tolerance of the chiral stationary phases were evaluated. The results demonstrated no remarkable difference in enantioseparation capability between natural and regenerated chitins based chiral stationary phases. The similar enantioseparation characteristics of two chiral stationary phases could be understood by comparing the IR spectra of related chitin derivatives One of the two chiral stationary phases prepared by coating the chitin derivative with a lower mol. weight generally provided better enantioseparations All chiral stationary phases can work in 100% chloroform, 100% Et acetate, 100% acetone, and the mobile phases containing a certain amount of THF. The chiral stationary phase prepared from the chitin derivative with the highest swelling capacity exhibited better enantioseparations than others. This chiral stationary phase was damaged by flushing with 100% THF; however, the enantioseparation capability was recovered again after the column was allowed to stand for 1 mo. Furthermore, the recovered chiral stationary phase provided better enantioseparations for some chiral analytes than before.

Journal of Separation Science published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C17H18N3NaO3S, HPLC of Formula: 161796-78-7.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Brammer, Matthew K. published the artcileCompatibility of doripenem with other drugs during simulated Y-site administration, Synthetic Route of 161796-78-7, the publication is American Journal of Health-System Pharmacy (2008), 65(13), 1261-1265, database is CAplus and MEDLINE.

The compatibility of doripenem diluted for infusion with 82 other drugs during simulated Y-site administration was studied. Five-milliliter samples of doripenem 5 mg/mL in 5% dextrose injection and sep. in 0.9% sodium chloride injection were combined with 5 mL of 82 other drugs, undiluted or diluted in 5% dextrose injection or 0.9% sodium chloride injection. Visual examinations were performed with the unaided eye in fluorescent light and using a Tyndall beam to enhance visualization of small particles and low-level turbidity. The turbidity of each sample was measured, and particulate content was evaluated. Samples were inspected initially and one and four hours after preparation Of the drugs tested, doripenem 5 mg/mL in 5% dextrose injection and in 0.9% sodium chloride injection was incompatible with diazepam, potassium phosphates, and undiluted propofol. Doripenem 5 mg/mL in 0.9% sodium chloride injection but not in 5% dextrose injection was incompatible with amphotericin B-containing drugs due to the diluent. Doripenem was found to be compatible when combined with the other 75 drugs for at least four hours. Doripenem 5 mg/mL in 5% dextrose injection or in 0.9% sodium chloride injection was phys. compatible for four hours at room temperature with 75 drugs during simulated Y-site administration. Three drugs combined with doripenem in 5% dextrose injection or 0.9% sodium chloride injection and 7 drugs combined with doripenem in 0.9% sodium chloride injection resulted in unacceptable precipitation or an increase in measured haze and should not be simultaneously administered with doripenem admixtures

American Journal of Health-System Pharmacy published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C17H18N3NaO3S, Synthetic Route of 161796-78-7.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Redondo, Jordi published the artcileHost-guest complexation of omeprazole, pantoprazole and rabeprazole sodium salts with cyclodextrins: an NMR study on solution structures and enantiodiscrimination power, Application In Synthesis of 161796-78-7, the publication is Journal of Inclusion Phenomena and Macrocyclic Chemistry (2012), 73(1-4), 225-236, database is CAplus.

The application of different cyclodextrins (CDs) as NMR chiral solvating agents (CSAs) for the sodium salts of the proton-pump inhibitors omeprazole, pantoprazole (sesquihydrate) and rabeprazole was investigated. It was proved that the formation of diastereomeric host-guest complexes in D₂O solution between the CDs and those substrates permitted the direct ¹H NMR discrimination of the enantiomers of the sodium salts of these compounds without the need of previous working-up. Rotating frame nuclear overhauser effect spectroscopy (ROESY) was used to ascertain the solution geometries of the host-guest complexes. The results suggested a preferential binding of the benzimidazole moiety of the guest mols. within the macrocyclic cavity of α-CD, whereas the higher dimensions of β- and γ-CD also permitted the inclusion of the highly substituted pyridine moieties. Moreover, the solution stoichiometries and the binding constants of the complexes formed with pantoprazole at room temperature were determined by ¹H and ¹⁹F NMR titration Diffusion-filtered Spectroscopy was applied to obtain clean spectra without the interference of the HOD signal.

Journal of Inclusion Phenomena and Macrocyclic Chemistry published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C17H18N3NaO3S, Application In Synthesis of 161796-78-7.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Yang, Fei published the artcilePerformances comparison of enantiomeric separation materials prepared from shrimp and crab shells, Quality Control of 161796-78-7, the publication is Carbohydrate Polymers (2019), 238-246, database is CAplus and MEDLINE.

Previously reported studies demonstrate that many chitin/chitosan derivatives are promising for enantioseparation of chiral compounds The aim of the present study is to study influence of the chitin sources on performances of the chitosan type enantiomeric separation materials. Therefore, the chitosans were prepared from crab and shrimp shells, from which two sets of chiral selector, i.e. chitosan bis(3,5-dimethylphenylcarbamate)-(octanamide)s and chitosan bis(3,5-dichlorophenylcarbamate)-(octanamide)s were synthesized. The chitosan bis(3,5-dimethylphenylcarbamate)-(octanamide)s, resp., derived from crab and shrimp shells were close in swelling capacity and enantioseparation capability, and the same feature was found for the other two chiral selectors of chitosan bis(3,5-dichlorophenylcarbamate)-(octanamide). However, although most of the chiral analytes were eluted out in the same elution order, there were two analytes were in reversed elution orders when separated by the two chiral stationary phases of chitosan bis(3,5-dichlorophenylcarbamate)-(octanamide). Based on the observed results, enantiomeric separation materials may be developed either with shrimp chitin or crab chitin, depending on the source accessibility.

Carbohydrate Polymers published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C8H11NO, Quality Control of 161796-78-7.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Chan, Pak published the artcileCompatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration, Formula: C17H18N3NaO3S, the publication is American Journal of Health-System Pharmacy (2008), 65(16), 1545-1551, database is CAplus and MEDLINE.

Purpose: The phys. compatibility of the new cephalosporin ceftobiprole medocaril with 70 other drugs during simulated Y-site injection was studied. Methods: Ceftobiprole was reconstituted with sterile water for injection. Dilutions of ceftobiprole 2 mg/mL (as ceftobiprole medocaril 2.67 mg/mL) were prepared in 5% dextrose injection, 0.9% sodium chloride injection, and lactated Ringer’s injection. For testing compatibility with the other drugs, a 5-mL sample of the ceftobiprole 2-mg/mL admixtures was combined with a 5-mL sample of the other drug either undiluted or diluted with one of the three vehicles. Each combination was prepared in duplicate, switching the order of drug addition, and kept at room temperature At intervals up to four hours after preparation, samples were examined visually and with the aid of a Tyndall beam and measured with a turbidimeter and a particle sizer and counter. Compatibility with propofol was evaluated by checking for emulsion separation and particles after centrifugation. Results: In all three vehicles, ceftobiprole was compatible with 31 other drugs and incompatible with 32. With 7 drugs, compatibility was dependent on the vehicle used. Signs of incompatibility included the presence of visible and subvisible particles, haze, and turbidity. No incompatibilities were related to the order of mixing. Conclusion: Of the 70 drugs evaluated for compatibility with ceftobiprole 2 mg/mL (as medocaril) in 5% dextrose injection, 0.9% sodium chloride injection, and lactated Ringer’s injection, 31 were found to be compatible and 32 were found to be incompatible in all three of the infusion solutions For 7 of the drugs, compatibility was dependent on which infusion solution was used. Ceftobiprole medocaril should not be simultaneously administered via a Y site with drugs with which it was shown to be incompatible.

American Journal of Health-System Pharmacy published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C17H18N3NaO3S, Formula: C17H18N3NaO3S.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem